Investors

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$44.13
Change (%) Stock is Down 1.58 (3.44%)
Volume3,555,496
Data as of 12/11/17 3:16 p.m. ET
Refresh quote
Featured Events
Webcast ImageWebcast
GBT Investor Webcast from the American Society of Hematology (ASH) 2017 Annual Meeting (Live)
12/11/17 at 8:15 p.m. ET
GBT Investor Webcast from the American Society of Hematology (ASH) 2017 Annual Meeting
Monday, December 11, 2017 8:15 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Presentation
Download Documentation Corporate Presentation (November 2017)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
12/11/17GBT Announces Presentation of Six Studies at ASH Supporting Voxelotor Sickle Cell Disease (SCD) Program
-- Highlights Include Compassionate Access Case Studies, Pediatric Pharmacokinetic Data and Burden of Care Data -- -- Company Plans to Announce Top-Line Data from Part A of Phase 3 HOPE Study in First Half of 2018 -- -- Company to Host Investor Webcast Today, Monday, December 11, at 8:15 p.m. ET/5:15 p.m. PT to Discuss SCD Program -- SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced results from six data pre... 
Printer Friendly Version
12/09/17GBT Announces New Phase 2a Data at ASH for Voxelotor in Adolescents with Sickle Cell Disease (SCD)
Data to be Highlighted in ASH Press Briefing and Company to Host Investor Webcast on Monday, December 11, at 8:15 p.m. ET/5:15 p.m. PT to Discuss Data SOUTH SAN FRANCISCO, Calif., Dec. 09, 2017 (GLOBE NEWSWIRE) --    Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced new results from its ongoing Phase 2a HOPE-KIDS 1 Study of once-daily oral therapy, voxelotor (previously called GBT440), a potentially disease-modifying therapy for adolescents with sickle cell disease (SCD). The... 
Printer Friendly Version
11/30/17Global Blood Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that the compensation committee of the Company’s board of directors granted two new employees inducement grants. The first employee received an option to purchase 15,000 shares of the Company’s common stock with a per share exercise price of $39.25, the closing trading price on the grant date of November 28, 2017. The second employee received an option to purchas... 
Printer Friendly Version
11/13/17Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease
Based on DSMB Review, Patients Age 12 to 17 Can Now be Enrolled in Phase 3 HOPE Study SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) announced today that the independent Data and Safety Monitoring Board (DSMB) for the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymErization) Study evaluating voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD), has completed its first sch... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
12/11/17 8:15 p.m. ET
GBT Investor Webcast from the American Society of Hematology (ASH) 2017 Annual Meeting
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.